Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,509 matching trials from the local directory fallback.

Filters: Cleveland, Ohio Clear all

Conditions: Knee Arthropathy, Knee Osteoarthritis, Surgery
Interventions: Personalized outcome prediction tool + targeted interventions, Standard of Care TKA; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Deep Venous Thrombosis
Interventions: Enoxaparin; Drug
Lead sponsor: Yale University; Other
Eligibility: Up to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 18 more

Conditions: Colorectal Cancer, Cutaneous Melanoma, Metastatic Uveal Melanoma, Other Solid Tumors
Interventions: Binimetinib, Crizotinib, IDE196; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more

Conditions: Insomnia Disorder
Interventions: Placebo, Tasimelteon Oral Suspension; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Dothan, Alabama • Phoenix, Arizona • Irvine, California + 17 more

Conditions: Chronic Idiopathic Constipation (CIC)
Interventions: Placebo, Tenapanor 25 mg BID, Tenapanor 5 mg BID, Tenapanor 50 mg BID; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 109
States / cities: Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more

Conditions: Liver Transplant Disorder
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: ATTR Amyloidosis Wild Type, ATTR Gene Mutation, ATTRV122I Amyloidosis, Cardiac Amyloidosis, Cardiomyopathy, Hypertrophic, Lumbar Spinal Stenosis
Interventions: Tc99-PYP or Tc99-HDMP Scan; Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 50 Years and older
Enrollment: 1,663 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Beverly Hills, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Prostate Cancer
Interventions: AAA617; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 24
States / cities: Scottsdale, Arizona • Orange, California • Santa Monica, California + 19 more

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation
Interventions: IFN-gamma-secreting HAdV antigen specific T cells; Biological
Lead sponsor: Mari Dallas; Other
Eligibility: 3 Months and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pediatric Asthma
Interventions: Healthy home intervention; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: Up to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Vascular Diseases
Interventions: Groin closure suture material, Groin closure with PDS suture; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cornea; Ectasia, Keratoconus, Refractive Errors
Interventions: Optical coherence tomography; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 16 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Familial Adenomatous Polyposis (FAP)
Interventions: Placebo, eRapa (encapsulated rapamycin); Drug
Lead sponsor: Rapamycin Holdings Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 18
States / cities: Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more

Conditions: Kidney Transplant Rejection
Interventions: HLA antibody, MMDx, Prospera; Diagnostic Test
Lead sponsor: University of Alberta; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 11
States / cities: Tampa, Florida • Baltimore, Maryland • Detroit, Michigan + 5 more

Conditions: Stress Urinary Incontinence, Vaginal Prolapse
Interventions: PAHG, RP-MUS; Procedure · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Neuropathic Pain
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chickenpox
Interventions: Hepatitis A vaccine, Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, MMR vaccine, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 1,840 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more

Conditions: Bleeding, Colorectal Disorders, Thromboembolism, Tranexamic Acid
Interventions: Tranexamic acid; Drug
Lead sponsor: Kristen Ban; Other
Eligibility: 18 Years to 100 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions: Oral repotrectinib (TPX-0005); Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 49
States / cities: Duarte, California • Glendale, California • La Jolla, California + 36 more

Conditions: Gastroschisis
Interventions: 35-week delivery, 38-week delivery; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 38
States / cities: Phoenix, Arizona • Loma Linda, California • Stanford, California + 30 more

Conditions: Locally Advanced Prostate Cancer, Malignant Neoplasm of Prostate
Interventions: 5-fraction Stereotactic Body Radiation Therapy (SBRT), Lu-PSMA-617; Radiation · Drug
Lead sponsor: Angela Y. Jia, MD PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Blood and urine samples collection, Blood samples for PK, SPECT/CT images, [111In]In-FL-020, [225Ac]Ac-FL-020; Procedure · Drug
Lead sponsor: Full-Life Technologies UK Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Duarte, California • Irvine, California • Stanford, California + 2 more

Conditions: HIV Infection, Menopause
Interventions: Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone, Transdermal estradiol gel; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Solid Tumors
Interventions: JAB-30355; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Denver, Colorado • Lake Mary, Florida • St Louis, Missouri + 4 more

Search by objective public record fields.

Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs Phenotypes

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

Humidity Asthma Interventions for Low Socioeconomic Status Children

CLOSM Trial: Groin Closure Using Layered Option for Suture Material

Corneal Elastography and Patient Specific Modeling

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Trifecta-Kidney cfDNA-MMDx Study

BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)

Brain Connectivity Changes With Spinal Cord Stimulation and Treatment of Chronic Pain: A Resting State NIRS/EEG Study

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Gastroschisis Outcomes of Delivery (GOOD) Study

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

Study With [225Ac]Ac-FL-020 in mCRPC Participants

Menopausal HT for Women Living With HIV (HoT)

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation